Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9
males and 9 females). The study consisted of three consecutive single-dose treatment periods
separated by a washout period of 7 days or more. On each treatment period, the volunteers
received a single dose of BIA 2-093 800 mg, orally.